Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, describes the new BCMA-targeting CAR T-cell therapy bb21217 and how it differs from idecabtagene vicleucel, the recently FDA-approved CAR T-cell therapy for myeloma.